All News

brain.mri2_.jpg

Cognitive Impairment in Patients with Rheumatoid Arthritis

d Akhil Sood, MD

Evidence suggests that RA patients are at increased risk for cognitive impairment. This is likely mediated by certain factors, including chronic inflammation and accelerated atherosclerosis. In the clinical setting, it is important to identify RA patients at increased risk for cognitive impairment.

Read Article
ACR Best

ACR21 Best Abstracts - Day 4

d Jack Cush, MD

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
Malar,rash,SLE, Lupus

Predictors of Remission and Low Disease Activity in SLE

d Sheila Reyes, MD

A treat-to-target strategy has been shown to improve clinical outcomes in patients with rheumatic diseases like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis including systemic lupus erythematosus.  The goal of treatment in SLE is aimed at remission or low disease activit

Read Article
After failing a JAK inhibitor, can you still hit a JAK-pot? Dr. Eric Dein ( @ericdeinmd) summarizes the abstracts presented at #ACR21. https://t.co/qRM7daiBmh https://t.co/yM0pT091i9

Links:

Dr. John Cush RheumNow ( View Tweet)
#ACR21 Best Abstracts - Day 2 The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2021 Day 2. https://t.co/Q6jCm29MN0 https://t.co/RTiifs5GxA

Links:

Dr. John Cush RheumNow ( View Tweet)
Management of Pain in Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0360 presented at the #ACR21 annual meeting. https://t.co/C6QU1J6E18 https://t.co/EAfXarQ976

Links:

Dr. John Cush RheumNow ( View Tweet)
Iberdomide for Lupus: Dr. Kathryn Dao ( @KDAO2011 ) discusses abstract #1458 presented at the #ACR21 annual meeting. https://t.co/viLtTG0tzB https://t.co/rdWTXaquDS

Links:

Dr. John Cush RheumNow ( View Tweet)
JAKi For Refractory Still’s Disease: Dr. Olga Petryna ( @DrPetryna) discusses abstract #0195 presented at the #ACR21 annual meeting. https://t.co/deSxncZOVP https://t.co/OJWGd4Osc4

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Dr. John Cush RheumNow ( View Tweet)

Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo) 🔹Prior-TNF vs TNF-naive: similar Significant improvement: 🔹ACR 20/50/70 & HAQ-DI 🔹TJC/SJC/enthesitis https://t.co/RV1zLpkUQe #ACR21 Abst#1820 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24. 🔹Randomized 173 pts 🔹52 weeks 🔹1° met (continued below) https://t.co/65ZXDjG9ur #ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)
Glucocorticoids (GC) in SLE on Belimumab 🔹Post-hoc, 5 phase 3 trials 🔹1° endpoint >25% pred↘️ to <7.5mg/d 🔹BEL n=1869; Placebo n=1217 🔹Baseline: 88% on GC; mean ~12.3mg/d pred 🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024) https://t.co/xp9LamlpHZ #ACR21 Abst#1283 @RheumNow

Links:

Pedro Castillo _Castillo_Pedro ( View Tweet)

#ICYMI #ACR21 Watch my interview with ⁦⁦@LatikaGupta_⁩ as she discusses the CoVAD study. @RheumNow ⁦@APLAR_org⁩ ⁦@rheumarhyme⁩ https://t.co/et0X7ltx3K

Links:

sheila RHEUMarampa ( View Tweet)

The amazing team @RheumNow and Dr.Kavanaugh are reviewing abstracts. #ACR21 https://t.co/kz8Y5mEgPN https://t.co/n0NMQ0P9uU

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
My Interview with Dr. Seoyoung Kim 👉🏼why/how she got into research 👉🏼her studies on CV risk w/HCQ, real world evidence CV risk w/Tofacitinib, gout T2T MACE occurrence @rheumnow #acr21 https://t.co/RjW5yfyWF6 via @YouTube

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Day 1 Report from #ACR21 The first full day of Abstracts and Presentations from ACR Convergence, the 2021 Virtual meeting, was full of highly engaging sessions, quality posters and unique presentations. https://t.co/hhuGBe8dwr https://t.co/I5dCzFd9SJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Dellaripa w/great talk on digital ischemia. Presents case of 25 yo F w/SLE, Class IV LN, APS, on apixaban, MMF, HCQ admitted w/AKI, ⬆️Upro & U-blood -> new HFrEF (EF 22%), tachy, & digital ischemia w/skin bx = thrombotic vasculopathy. #ACR21 Scientific Session 9T114 @RheumNow

Pedro Castillo _Castillo_Pedro ( View Tweet)

Had a blast with the @RheumNow team covering #ACR21! Eager to pour over more material over the coming weeks. What did folks do before the abstracts and videos were available online??

Pedro Castillo _Castillo_Pedro ( View Tweet)

Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Y... https://t.co/uxA00n1hxy via @YouTube Do watch my short commentary on the enhanced immuno-protection of 3rd primary #COVID dose in patients who are treated with rituximab #ACR21 @RheumNow

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

Risk of retinopathy vs #lupus flares. Do watch my interview with Dr Jorge on her works on issues surrounding hydroxyxhloroquine dose #ACR21 @RheumNow https://t.co/hKsAi4dD2n

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

×